JNJJohnson & Johnson
# 60 · $263.81 (-1.42%) · $635.07B · Healthcare
52-week range
Market data
- P/E
- 40.03
- 1M
- -2.54%
- 1Y
- +40.15%
- Yield
- 2.00%
- RSI
- 58.97
- MACD
- +0.42%
Breakdown
Why
- PEG of 0.44
- earnings growth of 90.6%
- ROE of 24.8%
- profit margin of 21.5%
- 12-1 momentum return of 43.8%
- trading 8.2% above 200d SMA
- MACD histogram positive
Rationale is generated by the scoring engine (English).
Piotroski F-Score
3
3 / 9 checks passed
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Risk signals
- Altman Z in grey zoneMedium
Z-Score 2.87 (1.81–2.99) — not clearly safe
- Earnings quality (accruals)Medium
operating cash flow below reported net income — profits not backed by cash
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Rising leverageInfo
debt/assets higher than the previous fiscal year
- Segment revenue concentrationInfo
64% of revenue from the Innovative Medicine segment
Company research
Business Overview Johnson & Johnson (JNJ) is a diversified healthcare company focused on Innovative Medicine (pharmaceuticals) and MedTech (medical devices & technology), generating revenue primarily from prescription medicine sales and medical device sales to healthcare providers and payors globally. Its portfolio spans major therapeutic areas (e.g., Immunology, Oncology, Neuroscience) and device categories (e.g., cardiovascular, surgery, vision, orthopaedics). Market Position JNJ is one of the world’s largest healthcare companies with broad scale across pharma and devices; competitive differentiation is driven by R&D, global commercial infrastructure, and a diversified portfolio across multiple disease areas and procedure categories. Demand is heavily influenced by reimbursement/third‑party payors and healthcare system pricing dynamics, particularly in the U.S. Key Segments JNJ reports two operating segments: Innovative Medicine and MedTech; in fiscal 2024, segment sales were approximately $57.0B (Innovative Medicine) and $31.9B (MedTech).
AI-generated summary based on third-party data; it may contain errors. Not investment advice or a recommendation to invest.
Period: 2021-12-31 → 2025-12-31